検索結果 - Emilio Alba

結果の絞り込み
  1. 1
    Playing only one instrument may be not enough: Limitations and future of the antiangiogenic treatment of cancer

    Playing only one instrument may be not enough: Limitations and future of the antiangiogenic treatment of cancer 著者: Ana R. Quesada, Miguel Ángel Medina, Emilio Alba

    出版事項 2007
    全文の入手 全文の入手
    Revisão
    お気に入りに追加
    保存先:
  2. 2
    The seed and soil hypothesis revisited: Current state of knowledge of inherited genes on prognosis in breast cancer

    The seed and soil hypothesis revisited: Current state of knowledge of inherited genes on prognosis in breast cancer 著者: Nuria Ribelles, Ángela Santonja, Bella Pajares, Casilda Llácer, Emilio Alba

    出版事項 2013
    全文の入手 全文の入手
    Revisão
    お気に入りに追加
    保存先:
  3. 3
    Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study

    Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study 著者: Antonio Rueda‐Domínguez, A. Márquez, Josep Gumà, Marta Llanos, J. Herrero, M Nieves, José Miramón, Emilio Alba

    出版事項 2004
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  4. 4
    Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review

    Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review 著者: Jesús García‐Foncillas, Emilio Alba, Enrique Aranda, Eduardo Díaz‐Rubio, Rafael López‐López, Josep Tabernero, Ana Vivancos

    出版事項 2017
    全文の入手 全文の入手
    Revisão
    お気に入りに追加
    保存先:
  5. 5
    Bevacizumab–Capecitabine (BEV–CAP) After Initial 1st-Line Bevacizumab–Docetaxel (BEV–DOC) in Patients (PTS) With HER2-Negative Metastatic Breast Cancer (MBC): Safety Analysis of the IMELDA Trial

    Bevacizumab–Capecitabine (BEV–CAP) After Initial 1st-Line Bevacizumab–Docetaxel (BEV–DOC) in Patients (PTS) With HER2-Negative Metastatic Breast Cancer (MBC): Safety Analysis of th... 著者: Joseph Gligorov, Emilio Alba-Conejo, José Bines, P. Cortes, Dinesh Doval, Zefei Jiang, Ulrich Freudensprung, Giorgio Mustacchi

    出版事項 2012
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  6. 6
    Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications

    Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications 著者: Ana Godoy-Ortiz, Alfonso Sánchez‐Muñoz, M Rosario Chica Parrado, Martina Álvarez, Nuria Ribelles, Antonio Rueda‐Domínguez, Emilio Alba

    出版事項 2019
    全文の入手 全文の入手
    Revisão
    お気に入りに追加
    保存先:
  7. 7
    Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response

    Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response 著者: Qingyang Xiao, André Nobre, Pilar Piñeiro, Miguel‐Ángel Berciano‐Guerrero, Emilio Alba, Manuel Cobo, Volker M. Lauschke, Isabel Barragán

    出版事項 2020
    全文の入手 全文の入手
    Revisão
    お気に入りに追加
    保存先:
  8. 8
    Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

    Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer 著者: Alfonso Sánchez‐Muñoz, Elena Gallego, Vanessa de Luque, Luis Gustavo Perez‐Rivas, Luís Vicioso, Nuria Ribelles, José Lozano, Emilio Alba

    出版事項 2010
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  9. 9
    Efficacy and Safety of Maintenance Bevacizumab (Bev) with or Without Capecitabine (Cap) After Initial First-Line Bev Plus Docetaxel (Doc) for Her2-Negative Metastatic Breast Cancer (Mbc): Imelda Randomised Phase III Trial

    Efficacy and Safety of Maintenance Bevacizumab (Bev) with or Without Capecitabine (Cap) After Initial First-Line Bev Plus Docetaxel (Doc) for Her2-Negative Metastatic Breast Cancer... 著者: Joseph Gligorov, D.C. Doval, José Bines, Z. Jiang, Emilio Alba, P. Cortes, Stefanie Srock, Sabine de Ducla, Ulrich Freudensprung, Giorgio Mustacchi

    出版事項 2014
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  10. 10
    GLIM Criteria Using Hand Grip Strength Adequately Predict Six-Month Mortality in Cancer Inpatients

    GLIM Criteria Using Hand Grip Strength Adequately Predict Six-Month Mortality in Cancer Inpatients 著者: Victoria Contreras-Bolívar, Francisco José Sánchez-Torralvo, María Dolores Martínez Ruíz, Inmaculada González-Almendros, Manuel Barrios, Susana Padín, Emilio Alba, Gabriel Olveira

    出版事項 2019
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  11. 11
    Challenges and achievements of liquid biopsy technologies employed in early breast cancer

    Challenges and achievements of liquid biopsy technologies employed in early breast cancer 著者: Alfonso Alba-Bernal, Rocío Lavado-Valenzuela, María Emilia Domínguez-Recio, Begoña Jiménez-Rodríguez, María Isabel Queipo‐Ortuño, Emilio Alba, Iñaki Comino‐Méndez

    出版事項 2020
    全文の入手 全文の入手
    Revisão
    お気に入りに追加
    保存先:
  12. 12
    Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study

    Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast... 著者: Emilio Alba, Miguel Martín, Manuel Ramos, Encarna Adrover, A. Balil, Carlos Jara, Agustí Barnadas, António Fernández, Pedro Sánchez‐Rovira, Margarita Amenedo, Antonio Casado

    出版事項 2004
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  13. 13
    Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2

    Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribocic... 著者: Sunil Verma, Joyce O’Shaughnessy, Howard A. Burris, Mario Campone, Emilio Alba, David Chandiwana, Anand A. Dalal, Santosh Sutradhar, Mauricio Monaco, Wolfgang Janni

    出版事項 2018
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  14. 14
    Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment

    Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment 著者: Aurora Laborda-Illanes, Lidia Sánchez‐Alcoholado, María Emilia Domínguez-Recio, Begoña Jiménez-Rodríguez, Rocío Lavado-Valenzuela, Iñaki Comino‐Méndez, Emilio Alba, María Isabel Queipo‐Ortuño

    出版事項 2020
    全文の入手 全文の入手
    Revisão
    お気に入りに追加
    保存先:
  15. 15
    A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression

    A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression 著者: Nuria Ribelles, J. Lopez-Siles, A. Bartolomé Sánchez, Emilio Esteban, María‐José Sánchez, F. Carabantes, P. Sanchez-Rovira, A. Márquez, Rosario Dueñas, Isabel Sevilla, Emilio Alba

    出版事項 2008
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  16. 16
    A microRNA Signature Associated with Early Recurrence in Breast Cancer

    A microRNA Signature Associated with Early Recurrence in Breast Cancer 著者: Luis Gustavo Perez‐Rivas, José M. Jerez, Rosario Carmona, Vanessa de Luque, Luís Vicioso, M. Gonzalo Claros, Enrique Viguera, Bella Pajares, Alfonso Sánchez, Nuria Ribelles, Emilio Alba, José Lozano

    出版事項 2014
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  17. 17
    Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines

    Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines 著者: Denis Talbot, Vladimir Moiseyenko, Simon Van Belle, S.M. O'Reilly, Emilio Alba, Stephen P. Ackland, Peter D. Eisenberg, David Melnychuk, Tadeusz Pieńkowski, H-U Burger, Siobhan Laws, B Osterwalder

    出版事項 2002
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  18. 18
    The role of ribociclib in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) early breast cancer: the EarLEE adjuvant clinical trials program

    The role of ribociclib in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) early breast cancer: the EarLEE adjuvant clinical trials progra... 著者: Michelino De Laurentiis, Filippo Montemurro, Thomas Bachelot, Miguel Martín, C.H. Barrios, Bella Kaufman, Peter Schmid, Emilio Alba, Véronique Dièras, S. Mondal, A. Chakravartty, Mark Shilkrut, Michelle C. Miller, Michael Untch

    出版事項 2017
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  19. 19
    Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer

    Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer 著者: Iñaki Comino‐Méndez, Jesús Velasco-Suelto, Javier Pascual, Esperanza López-López, María Elena Quirós-Ortega, Celia Gaona-Romero, Alejandro Martín-Muñoz, Patricia Losana, Yanira Heredia, Emilio Alba, Ángel Guerrero‐Zotano

    出版事項 2025
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  20. 20
    Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study

    Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study 著者: Nuria Ribelles, Javier Pascual, Laura Gálvez, Sofía Ruiz-Medina, Javier Garcia-Corbacho, José Carlos Benítez, María Emilia Domínguez-Recio, Esperanza Torres, L. Martinez Oliva, Manuel Zalabardo-Aguilar, Antonio Rueda, Emilio Alba

    出版事項 2024
    全文の入手
    Artigo
    お気に入りに追加
    保存先:

検索ツール: